These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. [Schizophrenic deficit syndrome and neurologic tolerance]. Verdoux H; Bourgeois M Encephale; 1996 Jun; 22 Spec No 2():45-7. PubMed ID: 8767042 [TBL] [Abstract][Full Text] [Related]
5. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Yamauchi K; Aki H; Tomotake M; Iga J; Numata S; Motoki I; Izaki Y; Tayoshi S; Kinouchi S; Sumitani S; Tayoshi S; Takikawa Y; Kaneda Y; Taniguchi T; Ishimoto Y; Ueno S; Ohmori T Psychiatry Clin Neurosci; 2008 Aug; 62(4):404-11. PubMed ID: 18778437 [TBL] [Abstract][Full Text] [Related]
6. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia. Kasper S Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918 [TBL] [Abstract][Full Text] [Related]
7. Food and Drug Administration commentary on methodological issues in negative symptom trials. Laughren T; Levin R Schizophr Bull; 2011 Mar; 37(2):255-6. PubMed ID: 21245124 [No Abstract] [Full Text] [Related]
8. Targeting information-processing deficit in schizophrenia: a novel approach to psychotherapeutic drug discovery. Hajós M Trends Pharmacol Sci; 2006 Jul; 27(7):391-8. PubMed ID: 16766049 [TBL] [Abstract][Full Text] [Related]
9. [Deficit: the value and difficulty of defining the primary or secondary character of observed symptoms]. Petit M; Langlois S Encephale; 1996 Jun; 22 Spec No 2():13-8. PubMed ID: 8767036 [TBL] [Abstract][Full Text] [Related]
10. Assessing negative symptoms and extrapyramidal symptoms in schizophrenia: workshop report. Kane JM; Dauphinais D; Barnes TR; Adler LA; Rifkin A Psychopharmacol Bull; 1993; 29(1):45-9. PubMed ID: 8104351 [No Abstract] [Full Text] [Related]
11. [Deficit schizophrenias]. Puech AJ Encephale; 1996 Jun; 22 Spec No 2():1. PubMed ID: 8767033 [No Abstract] [Full Text] [Related]
12. [Tolerance of neuroleptics, deficit syndrome and cognitive functions]. Kahn JP Encephale; 1996 Jun; 22 Spec No 2():49-54. PubMed ID: 8767043 [TBL] [Abstract][Full Text] [Related]
13. Auditory event-related potentials, auditory digit span, and clinical symptoms in chronic schizophrenic men on neuroleptic medication. Stefánsson SB; Jónsdóttir TJ Biol Psychiatry; 1996 Jul; 40(1):19-27. PubMed ID: 8780851 [TBL] [Abstract][Full Text] [Related]
14. [The problem of drug compliance in schizophrenic patients]. Albus M Psychiatr Prax; 1995 Nov; 22(6):221-2. PubMed ID: 8570750 [No Abstract] [Full Text] [Related]
15. New drugs for the treatment of schizophrenic patients. Fleischhacker WW Acta Psychiatr Scand Suppl; 1995; 388():24-30. PubMed ID: 7604735 [TBL] [Abstract][Full Text] [Related]
16. Schizophrenia: recent advances in psychopharmacology. Sharma T Br J Hosp Med; 1996 Feb 21-Mar 5; 55(4):194-8. PubMed ID: 8777500 [No Abstract] [Full Text] [Related]
17. New drug offers hope for people with schizophrenia. J Psychosoc Nurs Ment Health Serv; 1994 May; 32(5):46. PubMed ID: 7519676 [No Abstract] [Full Text] [Related]
18. [Effect of neuroleptics on depressive symptoms]. Tabeze JP Encephale; 1998 Jul; 24 Spec No 1():38-41. PubMed ID: 9809254 [No Abstract] [Full Text] [Related]
19. [Treatment of schizophrenia: what the family doctor should know]. Gruber O; Falkai P MMW Fortschr Med; 2008 May; 150 Suppl 2():16-9; quiz 20. PubMed ID: 18680837 [No Abstract] [Full Text] [Related]
20. [Clinical effects of clozapine: effect on negative symptoms]. Llorca PM; Lançon C; Auquier P; Bougerol T Encephale; 1996; 22(4):287-92. PubMed ID: 9035984 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]